Fig. 1From: Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case reportChanges in urinary protein, albumin, serum albumin and cholesterol after discontinuation of Pazopanib. Serum albumin(a) and cholesterol(b) levels before and after Pazopanib discontinuation. Changes in urine protein/creatinine ratio(c) and urine albumin/creatinine ratio(d) after discontinuation of PazopanibBack to article page